Analyst Price Targets — ETON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 14, 2026 12:40 pm | — | Canaccord Genuity | $68.00 | $56.43 | TheFly | Eton Pharmaceuticals price target raised to $68 from $60 at Canaccord |
| August 14, 2026 10:11 am | — | H.C. Wainwright | $70.00 | $40.80 | TheFly | Eton Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright |
| August 11, 2026 10:51 am | Swayampakula Ramakanth | H.C. Wainwright | $65.00 | $43.67 | StreetInsider | Eton Pharmaceuticals (ETON) PT Raised to $65 at H.C. Wainwright |
| July 28, 2026 1:16 pm | — | Craig-Hallum | $62.00 | $45.04 | TheFly | Eton Pharmaceuticals price target raised to $62 from $40 at Craig-Hallum |
| July 16, 2026 8:11 pm | — | Canaccord Genuity | $60.00 | $37.19 | TheFly | Eton Pharmaceuticals initiated with a Buy at Canaccord |
| May 15, 2026 1:55 pm | — | H.C. Wainwright | $57.00 | $29.21 | TheFly | Eton Pharmaceuticals price target raised to $57 from $52 at H.C. Wainwright |
| May 29, 2025 10:24 am | — | H.C. Wainwright | $35.00 | $18.92 | TheFly | Eton Pharmaceuticals price target raised to $35 from $33 at H.C. Wainwright |
| October 28, 2024 9:31 am | Chase Knickerbocker | Craig-Hallum | $15.00 | $8.44 | StreetInsider | Eton Pharmaceuticals (ETON) PT Raised to $15 at Craig-Hallum |
| October 4, 2024 6:13 am | Swayampakula Ramakanth | H.C. Wainwright | $11.00 | $6.91 | TheFly | Eton Pharmaceuticals price target raised to $11 from $9 at H.C. Wainwright |
| May 6, 2024 7:29 am | Chase Knickerbocker | Craig-Hallum | $8.00 | $3.71 | TheFly | Eton Pharmaceuticals initiated with a Buy at Craig-Hallum |
Latest News for ETON
Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,150 shares of the company's stock, valued at approximately $476,000. Other large investors have also
BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833 shares of the company's stock, valued at approximately $68,629,000. BlackRock Inc. owned about 6.92% of Eton Pharmaceuticals at the
Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 144,367 shares of the company's stock after purchasing an additional 39,571 shares
Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,200 shares of the company's stock, valued at approximately $623,000. Bank of Nova Scotia owned about
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ETON.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.